Extract

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Inclusion criteria

• Chronic lymphocytic leukemia ,Small Lymphocytic Lymphoma

Country

• Australia
• China
• Malaysia
• Taiwan, Province of China

Links

• ictrp
• nct